Traders Buy Johnson & Johnson (JNJ) on Weakness

Share on StockTwits

Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Thursday. $513.55 million flowed into the stock on the tick-up and $285.40 million flowed out of the stock on the tick-down, for a money net flow of $228.15 million into the stock. Of all companies tracked, Johnson & Johnson had the highest net in-flow for the day. Johnson & Johnson traded down ($3.89) for the day and closed at $133.84

JNJ has been the topic of a number of research reports. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, July 13th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price objective on the stock. Finally, Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $143.91.

The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. The firm has a market cap of $370.70 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 2.19 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter in the previous year, the firm earned $1.83 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in JNJ. Financial Gravity Wealth Inc. purchased a new position in shares of Johnson & Johnson in the first quarter worth $105,000. Selective Wealth Management purchased a new position in shares of Johnson & Johnson in the third quarter worth $105,000. CSat Investment Advisory L.P. purchased a new position in shares of Johnson & Johnson in the second quarter worth $107,000. WP Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $108,000. Finally, FNY Investment Advisers LLC bought a new stake in Johnson & Johnson in the second quarter worth $117,000. 66.67% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What is a Call Option?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply